News | February 23, 2022
Biorchestra announces US$45 million series C fundraising
he financing was significantly oversubscribed with high demand from both existing and new investors.
he financing was significantly oversubscribed with high demand from both existing and new investors.
Adds to Merck’s growing global, multi-modality CDMO network, following newly formed CDMO business unit in Life Science
Robust pipeline with around 50 projects in clinical development / cardiology portfolio poised for growth with launch products Kerendia (finerenone) and Verquvo (vericiguat)
Therapeutic use of the product is for short term symptomatic relief of colds, chills and influenza including chesty coughs
The COVID-19 pandemic has triggered the rapid growth of the biotherapeutics market
He will be responsible for developing the company's pipeline of partnered and in-house discovery programs,
US $ 555,000 invested by Wavemaker Partners in pre-seed round
To be marketed by Strides Pharma Inc. in the US market
The transaction generates upfront cash proceeds of $442 million for Syncona's holding in Gyroscope
Since the beginning of the pandemic, more than one million patients with severe COVID-19 have been treated with Actemra/RoActemra
Subscribe To Our Newsletter & Stay Updated
